On this page, we spotlight clinical sites participating in ARLG studies. Their contributions to the mission of ARLG are essential in combating the antibacterial resistance crisis and improving patient care. Join us in learning more about sites on the front lines of researching antibacterial resistance.
Mayo Clinic
W. Charles Huskins, MD, MSc, collaborated with colleagues across the ARLG to design and conduct the SCOUT-CAP study. The study found that a five-day course of antibiotics was superior to the standard 10-day course; the short course led to similar clinical outcomes while reducing antibiotic exposure and resistance. Dr. Huskins and other principal investigators have led multidisciplinary research teams to conduct several ARLG studies at Mayo Clinic. Their work has helped to advance clinical research and improve the care of patients with antibacterial-resistant infections.
University of North Carolina
Dr. David van Duin and the Infectious Diseases Clinical Trial Team at the University of North Carolina (UNC) have participated in several ARLG research activities. Dr. van Duin, Director of the Immunocompromised Host Infectious Diseases Program at UNC Health, served as the Principal Investigator for the MDRO Network and the CRACKLE and SHREC studies.
University of Pittsburgh
As one of three world-class Centers of Excellence in Research within the University of Pittsburgh’s Division of Infectious Diseases, the Center for Innovative Antimicrobial Therapy (CIAT) investigates novel approaches to address the growing public health crisis of antimicrobial resistance. These investigators, researchers, and study coordinators are part of a stellar team with a long history of partnering on ARLG studies.
Corewell Health
Dr. Matthew Sims and his clinical trial team at Corewell Health, the largest health care system in Michigan, have worked on many ARLG studies like ACUMIN and DOTS, and are currently working on studies like OPTIMIZE-GNI and Pneumonia Direct Pilot (PDP).
Henry Ford Health
Henry Ford Health is an academic institution composed of 13 hospitals, making it the second largest health system in the state of Michigan. The main location for research is in Detroit at Henry Ford Hospital—a quaternary referral hospital housing 877 beds. They take great pride in serving a wide population, and it shows in their clinical trial enrollment as well.